

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 6

ATTY. DOCKET NO.

ON/4-32717A

APPLICATION NO.

10/530,452

APPLICANT

DE BONT ET AL.

FILING DATE

SEPTEMBER 9, 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
WWW/	AA	2,960,504	11/15/60	Druey et al.			
WWW/	AB	3,753,988	8/21/73	Rodway et al.			
WWW/	AC	4,665,181	5/12/87	Thomas et al.			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
WWW/	AM	*98 35958	8/20/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
WWW/	AN	*02 41882	5/30/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
WWW/	AO	*03 035047	5/1/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
WWW/	AP	*03 022282	3/20/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
WWW/	AQ	*03 059354	7/24/03	WO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

WWW/	AR	*Mesters R. M. et al., "Angiogenesis Bei Haematologischen Neoplasien," Onkologie, Vol. 24, No. Suppl. 5, pp. 75-80 (2001) (English abstract)
WWW/	AS	*Wood, "Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy," Medicina, Vol. 60, No. Suppl 2, pp. 41-47 (2000)
WWW/	AT	*Wood et al., "PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration," Cancer Research, Vol. 60, No. 8, p. 2178-2189 (2000)

EXAMINER /Walter Webb/ DATE CONSIDERED 08/21/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32717A
APPLICATION NO.
10/530,452
APPLICANT
DE BONT ET AL.
FILING DATE
SEPTEMBER 9, 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/WWW/	BM	3-106875	5/7/91	JP (English translation)			<input type="checkbox"/>	<input type="checkbox"/>
/WWW/	BN	3-106873	5/7/91	JP (English translation)			<input type="checkbox"/>	<input type="checkbox"/>
/WWW/	BO	361,812	6/30/62	CH (English abstract)			<input type="checkbox"/>	<input type="checkbox"/>
/WWW/	BP	07224067	8/22/95	JP (English abstract)			<input type="checkbox"/>	<input type="checkbox"/>
/WWW/	BQ	3106872	5/7/91	JP (English abstract)			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/WWW/	BR	*Lin et al., "The VEGF receptor tyrosine kinase inhibitor PTK787 inhibits proliferation and migration of multiple myeloma cells, and reduces paracrine-mediated responses to the bone marrow microenvironment," Blood, Vol. 98, No. 11, pp. 166A (2001)
/WWW/	BS	*Traxler et al., "Tyrosine kinase inhibitors: from rational design to clinical trials," Medicinal Research Reviews, Vol. 21, No. 6, pp. 499-512 (2001)
/WWW/	BT	*Roboz et al., "Phase I trial of PTK787/ZK 222584, a inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in acute myeloid leukemia and myelodysplastic syndrome," Blood, Vol. 100, No. 11, pp. Abstract No. 1308 (2002)

EXAMINER

/Walter Webb/

DATE CONSIDERED

08/21/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32717A
APPLICATION NO.
10/530,452
APPLICANT
DE BONT ET AL.
FILING DATE
SEPTEMBER 9, 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
WWW	BM	3106874	5/7/91	JP (English Abstract)			<input type="checkbox"/>	<input type="checkbox"/>
WWW	BN	516563	1/31/72	CH (English Abstract)			<input type="checkbox"/>	<input type="checkbox"/>
WWW	BO	00 59509	10/12/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
WWW	BP	02 089772	11/14/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

WWW	BR	"Escribano et al., "Expression of the C-kit (CD117) molecule in normal and malignant hematopoiesis," Vol. 30, No. 5/6, pp. 459-466 (1998)
WWW	BS	Watanabe et al., "4-benzylamino-1-chloro-6-substituted phthalazines: synthesis and inhibitory activity toward phosphodiesterase 5," J. Med. Chem., Vol. 41, pp. 3367-3372 (1998)
WWW	BT	O'Reilly et al., "Angiostatin induces and sustains dormancy of human primary tumors in mice," Nature Medicine, Vol. 2, No. 6, pp. 689-692 (1996)

EXAMINER /Walter Webb/

DATE CONSIDERED

08/21/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32717A
APPLICATION NO.
10/530,452
APPLICANT
DE BONT ET AL.
FILING DATE
SEPTEMBER 9, 2005

Group

EXAMINER
INITIAL**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

WWW/	DA	Wagaw et al., "The synthesis of aminopyridines: a method employing palladium-catalyzed carbon-nitrogen bond formation," J. Org. Chem., Vol. 61, pp. 7240-7241 (1996)
	DB	Haworth et al., "Synthetic antimalarials, Part XXVII. Some derivatives of phthalazine, quinoxaline, and isoQuinoline," J. Chem. Soc., Vol. 25, pp. 777-782 (1948)
	DC	Yamaguchi et al., "Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-imidazolyl)alkyl]-1(2H)-phthalazinones," J. Med. Chem., Vol 36, pp. 4052-4060 (1993)
	DD	Seed, "Angiogenesis inhibition as a drug target for disease: an update," Exp. Opin. Invest. Drugs, Vol. 5, No. 12 pp. 1617-1637 (1996)
	DE	Hennequin et al., "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors," J. Med. Chem. Vol. 42, pp. 5369-5389 (1999)
	DF	Ishihara et al., "Pharmacological Characterization of a novel, potent and selective phosphodiesterase 5 inhibitor, E4010," Jpn. J. Pharmacol., Vol. 76, p. 175ff. (1998)
	DG	Chemical Abstracts, No. 115-256197a, Vol. 115, No. 23 (1991)
	DH	Schuler et al., "The relation of the hypotensive and reserpine-antagonizing effects of hydrazine derivatives to enzyme- and metal-catalysis of biogenic amines in vitro," Arch. Int. Pharmacodyn., CXXXVIII, 3-4, pp. 431-468 (1960); Abstract CA 55:11654 (1961)
↓	DI	Dreys et al., "Effects of PTK787/ZK 222584, a specific vascular endothelial growth factor (VEGF)-receptor tyrosine kinase inhibitor, on primary tumor, metastasis, vessel density and blood flow in a murine renal cell carcinoma," pp. 1-22
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

Walter Webb/

DATE CONSIDERED

08/21/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32717A
APPLICATION NO.
10/530,452
APPLICANT
DE BONT ET AL.
FILING DATE
SEPTEMBER 9, 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/WW/	BM	871753	6/28/61	GB			<input type="checkbox"/>	<input type="checkbox"/>
/WW/	BN	0722936	7/24/96	EP			<input type="checkbox"/>	<input type="checkbox"/>
/WW/	BO	1293565	6/18/72	GB			<input type="checkbox"/>	<input type="checkbox"/>
/WW/	BP	1 133 406	11/13/68	GB			<input type="checkbox"/>	<input type="checkbox"/>
/WW/	BQ	97 26258	7/24/97	WO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	
	BS	
	BT	

EXAMINER /Walter Webb/

DATE CONSIDERED 08/21/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32717A
APPLICATION NO.
10/530,452
APPLICANT
DE BONT ET AL.
FILING DATE
SEPTEMBER 9, 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/WWW/	BM	97 40020	10/30/97	WO (abstract only)			<input type="checkbox"/>	<input type="checkbox"/>
/WWW/	BN	0600831	6/8/94	EP (abstract only)			<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	
	BS	
	BT	

EXAMINER	/Walter Webb/	DATE CONSIDERED	08/21/2007
----------	---------------	-----------------	------------

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.